Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer
The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer. The name of the study intervention used in this research study is: Psilocybin (a tryptamine derivative)
- Status
- recruiting
- Phase
- Phase 2
- Institution
- Yvan Beaussant, MD, MSci
- Principal investigator
- Yvan Beaussant, MD
- Start date
- 2024-09-23
- End date
- 2026-12-31
- Registry ID
- NCT06001749
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.